SCHEMBL1355852

SCHEMBL1355852

COc1cccc(-n2ncc3cnc(Nc4ccc(N5CCOCC5)cc4)nc32)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR4 P22455 4/20 0.63
CDK4 P11802 3/20 0.60
AURKA O14965 1/20 0.60
CSF1R P07333 4/20 0.56
LCK P06239 2/20 0.56
STAT6 P42226 1/20 0.54
DAPK1 P53355 1/20 0.54
BRD4 O60885 3/20 0.52
EGFR P00533 1/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
FGFR1 P11362 2/20 0.51
CCND1 P24385 2/20 0.51
CDK1 P06493 1/20 0.51
CCNB1 P14635 1/20 0.51
CCNE1 P24864 1/20 0.51
CDK2 P24941 1/20 0.51
PDGFRB P09619 1/20 0.51
SLC2A1 P11166 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1355798 0.90 CDK4 (0.73) FGFR4CDK4AURKALCKBRD4
SCHEMBL1355170 0.90 EIF2AK4 (0.61) FGFR4CDK4AURKACSF1RLCK
SCHEMBL1356819 0.90 CDK4 (0.59) FGFR4CDK4AURKABRD4EGFR
SCHEMBL1353747 0.86 AURKA (0.58) FGFR4CDK4AURKALCKBRD4
SCHEMBL1356713 0.84 MAPT (0.51) FGFR4CDK4AURKABRD4EGFR
SCHEMBL1355529 0.84 EIF2AK4 (0.53) CDK4AURKABRD4EGFRNPC1
SCHEMBL1356097 0.81 MAPT (0.52) CDK4AURKACSF1RLCKNPC1
SCHEMBL1355752 0.81 EIF2AK4 (0.62) FGFR4CDK4AURKAEGFRNPC1
SCHEMBL1355678 0.81 TUBB4A (0.48) CDK4AURKABRD4NPC1RAB9A
SCHEMBL1355600 0.81 SYK (0.54) CDK4AURKASTAT6CCND1CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110281821-A9 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2011-11-17 US claimed
US-20100249067-A1 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2010-09-30 US claimed
EP-2108020-A2 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES Biogen Idec MA, Inc. (US) 2009-10-14 EP claimed
WO-2008094602-A2 1-H-PYRAZOLO (3,4B) PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES BIOGEN IDEC MA INC. (US) 2008-08-07 WO claimed
US-20110281821-A9 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2011-11-17 US disclosed
US-20100249067-A1 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2010-09-30 US disclosed
EP-2108020-A2 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES Biogen Idec MA, Inc. (US) 2009-10-14 EP disclosed
WO-2008094602-A2 1-H-PYRAZOLO (3,4B) PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES BIOGEN IDEC MA INC. (US) 2008-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249067-A1 Modulators of Mitotic Kinases BUB1, BUB1B, CDK1 FGFR4 1543/4885CDK4 101/4885AURKA 9/4885
US-20110281821-A9 Modulators of Mitotic Kinases BUB1, BUB1B, CDK1 FGFR4 1543/4885CDK4 101/4885AURKA 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.